Bromodomain and extra-terminal domain (BET) proteins
play an important
role in epigenetic regulation and are linked to several diseases;
therefore, they are interesting targets. BET has two bromodomains:
bromodomain 1 (BD1) and BD2. Selective targeting of BD1 or BD2 may
produce different activities and greater effects than pan-BD inhibitors.
However, the selective mechanism of the specific core must be studied
at the atomic level. This study determined the effectiveness of pyrrolopyridone
analogues to selectively inhibit BD2 using a pan-BD inhibitor (ABBV-075)
and a selective-BD2 inhibitor (ABBV-744). Molecular dynamics simulations
and calculations of binding free energies were used to systematically
study the selectivity of BD2 inhibition by the pyrrolopyridone analogues.
Overall, the pyrrolopyridone analogue inhibitors targeting BD2 interacted
mainly with the following amino acid pairs between bromodomain-containing
protein 4 (BRD4)-BD1 and BRD4-BD2 complexes: I146/V439, N140/N433,
D144/H437, P82/P375, V87/V380, D88/D381, and Y139/Y432. The pyrrolopyridone
analogues targeting BRD4-BD2 were divided into five regions based
on selectivity mechanism. These results suggest that the R3 and R5
regions of pyrrolopyridone analogues can be modified to improve the
selectivity between BRD4-BD1 and BRD4-BD2. The selectivity of BD2
inhibition by pyrrolopyridone analogues can be used to design novel
BD2 inhibitors based on a pyrrolopyridone core.